Dymicron®, a privately held medical device company pioneering advanced spinal technologies, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to begin a pivotal clinical study of the Triadyme®‑C cervical artificial disc. This achievement marks a critical milestone in the company’s mission to bring the...

Dymicron® is proud to be recognized in the annual listing of 10 companies at the forefront of biomechanics solutions.

Dymicron’s Triadyme-C Artificial Cervical Disc won the 2021 Best New Spine Technology Award presented by Orthopedics This Week.

Dymicron has developed a next-generation man-made diamond material for orthopedic applications in its Triadyme®-C artificial cervical disc replacement.